ALK-tyrosine kinase inhibitors (ALK-TKIs) and EGFR-TKIs are recommended as the standard of care for NSCLC patients with ALK rearrangements or EGFR mutations, respectively (6). This evidence concerns the gene ALK and non-small cell lung carcinoma.